Evidence map›Paper›PMID 35499053›Full record

ArticleJournal of advanced research2022

Epidemiological and sociodemographic transitions of female breast cancer incidence, death, case fatality and DALYs in 21 world regions and globally, from 1990 to 2017: An Age-Period-Cohort Analysis.

Sumaira Mubarik, Yong Yu, Fang Wang, Saima Shakil Malik, Xiaoxue Liu, Muhammad Fawad, Fang Shi, Chuanhua Yu

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Sumaira MubarikDepartment of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan 430071, China.
Yong YuSchool of Public Health and Management, Hubei University of Medicine, 30# South Renmin Road, Shiyan, Hubei 442000, China.
Fang WangDepartment of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan 430071, China.
Saima Shakil MalikDepartment of Genetics, The University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Xiaoxue LiuDepartment of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan 430071, China.
Muhammad FawadZhengzhou Key Laboratory of Big Data Analysis and Application, Henan Academy of Big Data, Zhengzhou University, Zhengzhou 450052, China.
Fang ShiDepartment of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan 430071, China.
Chuanhua YuDepartment of Epidemiology and Biostatistics, School of Health Sciences, Wuhan University, Wuhan 430071, China.
Wuhan University · CNHubei University of Medicine · CNUniversity of Alabama at Birmingham · USZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Breast cancer (BC) is the most widely studied disease due to its higher prevalence, heterogeneity and mortality. Objectives: This study aimed to compare female BC trends among 21 world regions and globally over 28 year of data and to assess the association between sociodemographic transitions and female BC risks. Methods: We used Global burden of disease study data and measure the female BC burden according to 21 world regions and sociodemographic indices (SDI). Age-period-cohort (APC) analysis was used to estimate time and cohort trend of BC in different SDI regions. Results: By world regions, age-standardised rate of female BC incidence were high in high-income-North America (ASR, 92.9; (95 %UI, 89.2, 96.6)), Western Europe (84.7; (73.4, 97.2)) and Australia (86; (81.7, 90.2)) in 2017. Whereas this rate was significantly increased by 89.5% between 1990 and 2017 in East Asia. We observed negative association between SDI and death, and DALYs in 25th and below percentiles of death and DALYs for the worldwide regions. Further, there was observed a strong negative correlation between SDI and case fatality percent (r Conclusions: Remarkable variations exist among various regions in BC burden. There is a need to reduce the health burden from BC in less developed and under developing countries, because under-developed countries are facing higher degree of health-related burden. Public health managers should execute more classified and cost-effective screening and treatment interferences to lessen the deaths caused by BC, predominantly among middle and low SDI countries having inadequate healthcare supplies.

Indexed as

Breast NeoplasmsGlobal Burden of DiseaseCohort StudiesDisability-Adjusted Life YearsFemaleGlobal HealthHumansIncidenceQuality-Adjusted Life YearsAge-period-cohortAPC, age-period-cohortASDR, age-standardized death ratesASIR, age-standardized incidence ratesBC, breast cancerBreast cancerCase fatalityCFP, case-fatality-percentCFR, case-fatality ratesDALYs, disability adjusted life yearsDR, death ratesGBD, global burden of diseasesIncidenceIR, incidence ratesSDI, sociodemographic indexWorld regionsYLDs, years lived with disabilityYLLs, years of life lost

Identifiers

PMID35499053
PMCPMC9039678
OpenAlexW3188738475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.